Injecting Drug Use Medication

1. United Nations Office on Drugs and Crime. World Drug Report 2015. UNODC. Available at http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf. May 2015; Accessed: March 31, 2016.

2. Doherty MC, Garfein RS, Monterroso E. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000 Apr 14. 14(6):717-26. [Medline].

3. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999 Dec 27. 107(6B):2S-9S. [Medline].

4. Boodram B, Hershow RC, Cotler SJ, Ouellet LJ. Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users. Drug Alcohol Depend. 2011 Dec 15. 119(3):166-71. [Medline]. [Full Text].

5. Des Jarlais DC, Hagan H, Arasteh K, et al. Can intranasal drug use reduce HCV infection among injecting drug users?. Drug Alcohol Depend. 2011 Dec 15. 119(3):201-6. [Medline].

6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2003. 2004. 15:[Full Text].

7. Bennett GA, Velleman RD, Barter G. Gender differences in sharing injecting equipment by drug users in England. AIDS Care. 2000 Feb. 12(1):77-87. [Medline].

8. Becker Buxton M, Vlahov D, Strathdee SA. Association between injection practices and duration of injection among recently initiated injection drug users. Drug Alcohol Depend. 2004 Aug 16. 75(2):177-83. [Medline].

9. Petersen Z, Myers B, van Hout MC, Plüddemann A, Parry C. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. Harm Reduct J. 2013 Aug 19. 10:13. [Medline].

10. Macarthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2013 Aug 20. [Medline].

11. Landau J, Garrett J, Shea RR. Strength in numbers: the ARISE method for mobilizing family and network to engage substance abusers in treatment. A Relational Intervention Sequence for Engagement. Am J Drug Alcohol Abuse. 2000 Aug. 26(3):379-98. [Medline].

12. FDA Okays Handheld Autoinjector for Opioid Overdose. Medscape. Available at http://www.medscape.com/viewarticle/823039. Accessed: April 3, 2014.

13. Centers for Disease Control and Prevention. Cases of HIV Infection and AIDS in the United States, by Race/Ethnicity, 2000-2004. HIV/AIDS Surveillance Supplemental report. 2006. 12 (1):[Full Text].

14. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis. 2000 Feb. 30(2):374-9. [Medline].

15. Macalino GE, Springer KW, Rahman ZS. Community-based programs for safe disposal of used needles and syringes. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. 18 Suppl 1:S111-9. [Medline].

16. Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998 Jun. 113 Suppl 1:19-30. [Medline].

17. Deren S, Cleland CM, Fuller C, Kang SY, Des Jarlais DC, Vlahov D. The impact of syringe deregulation on sources of syringes for injection drug users: preliminary findings. AIDS Behav. 2006 Nov. 10(6):717-21. [Medline].

18. Obadia Y, Feroni I, Perrin V. Syringe vending machines for injection drug users: an experiment in Marseille, France. Am J Public Health. 1999 Dec. 89(12):1852-4. [Medline].

19. Tun W, Vu L, Adebajo SB, Abiodun L, Sheehy M, Karlyn A, et al. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria. Int J STD AIDS. 2013 Jul 19. [Medline].

20. Eskandarieh S, Nikfarjam A, Tarjoman T, Nasehi A, Jafari F, Saberi-Zafarghandi MB. Descriptive Aspects of Injection Drug Users in Iran's National Harm Reduction Program by Methadone Maintenance Treatment. Iran J Public Health. 2013. 42(6):588-93. [Medline]. [Full Text].

21. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect. 2006 Jun. 82 Suppl 3:iii10-17. [Medline].

22. Aceijas C, Oppenheimer E, Stimson GV, Ashcroft RE, Matic S, Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction. 2006 Sep. 101(9):1246-53. [Medline].

23. Ball AL, Rana S, Dehne KL. HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Rep. 1998 Jun. 113 Suppl 1:170-81. [Medline].

24. Beck EJ, Mandalia S, Williams I. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. AIDS. 1999 Oct 22. 13(15):2157-64. [Medline].

25. Brunton C, Kemp R, Raynel P. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. N Z Med J. 2000 Mar 24. 113(1106):98-101. [Medline].

26. Carrieri MP, Moatti JP, Vlahov D. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health. 1999 Jan. 53(1):4-8. [Medline].

27. Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998 Jun. 21(6):701-10. [Medline].

28. Contoreggi C, Rexroad VE, Lange WR. Current management of infectious complications in the injecting drug user. J Subst Abuse Treat. 1998 Mar-Apr. 15(2):95-106. [Medline].

29. Des Jarlais DC, Friedman SR. Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep. 1998 Jun. 113 Suppl 1:182-8. [Medline].

30. Gostin LO, Lazzarini Z, Jones TS. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. A national survey on the regulation of syringes and needles. JAMA. 1997 Jan 1. 277(1):53-62. [Medline].

31. Gowing L, Farrell M, Bornemann R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004. CD004145. [Medline].

32. Hughes PH, Rieche O. Heroin epidemics revisited. Epidemiol Rev. 1995. 17(1):66-73. [Medline].

33. Hughes RA. Drug injectors and the cleaning of needles and syringes. Eur Addict Res. 2000 Mar. 6(1):20-30. [Medline].

34. Hulse GK, English DR, Milne E. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999 Feb. 94(2):221-9. [Medline].

35. Kaye S, Darke S. A comparison of the harms associated with the injection of heroin and amphetamines. Drug Alcohol Depend. 2000 Feb 1. 58(1-2):189-95. [Medline].

36. Lennings CJ. Harm minimization or abstinence: an evaluation of current policies and practices in the treatment and control of intravenous drug using groups in Australia. Disabil Rehabil. 2000 Jan 10-20. 22(1-2):57-64. [Medline].

37. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy. 2007 Aug. 18(4):255-61. [Medline].

38. Leshner AI. Science-based views of drug addiction and its treatment. JAMA. 1999 Oct 13. 282(14):1314-6. [Medline].

39. Martin V, Cayla JA, Bolea A. Mycobacterium tuberculosis and human immunodeficiency virus co-infection in intravenous drug users on admission to prison. Int J Tuberc Lung Dis. 2000 Jan. 4(1):41-6. [Medline].

40. Massad E, Rozman M, Azevedo RS. Seroprevalence of HIV, HCV and syphilis in Brazilian prisoners: preponderance of parenteral transmission. Eur J Epidemiol. 1999 May. 15(5):439-45. [Medline].

41. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine. 1999 Mar 26. 17(13-14):1730-3. [Medline].

42. Mclean L, Sharma S. Mycotic pulmonary arterial aneurysms in an intravenous drug user. Canadian Respiratory J. 1998. 5(4):307-11.

43. Metzger DS, Woody GE, McLellan AT. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993 Sep. 6(9):1049-56. [Medline].

44. Moatti JP, Carrieri MP, Spire B. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000 Jan 28. 14(2):151-5. [Medline].

45. Molitor F, Ruiz JD, Flynn N. Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users. Am J Drug Alcohol Abuse. 1999 Aug. 25(3):475-93. [Medline].

46. Neaigus A, Gyarmathy VA, Miller M, Frajzyngier V, Zhao M, Friedman SR. Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend. 2007 Jul 10. 89(2-3):234-43. [Medline].

47. Powis B, Strang J, Griffiths P. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction. 1999 Apr. 94(4):471-8. [Medline].

48. Rhodes F, Deren S, Wood MM. Understanding HIV risks of chronic drug-using men who have sex with men. AIDS Care. 1999 Dec. 11(6):629-48. [Medline].

49. Shapiro CN, Coleman PJ, McQuillan GM. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine. 1992. 10 Suppl 1:S59-62. [Medline].

50. Smith AM, Lindsay J, Rosenthal DA. Same-sex attraction, drug injection and binge drinking among Australian adolescents. Aust N Z J Public Health. 1999 Dec. 23(6):643-6. [Medline].

51. Smith DK, Grohskopf LA, Black RJ. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005 Jan 21. 54(RR-2):1-20. [Medline].

52. Stimson GV, Fitch C, Rhodes T. The rapid assessment and response guide on injecting drug use. World Health Organization, Substance Abuse Department; 1998.

53. Strang J, Powis B, Best D. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999 Feb. 94(2):199-204. [Medline].

54. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH report: Demographic and Geographic Variations in Injection Drug Use. 2007. [Full Text].

55. Thorne LB, Collins KA. Speedballing with needle embolization: case study and review of the literature. J Forensic Sci. 1998 Sep. 43(5):1074-6. [Medline].

56. UNAIDS. AIDS Epidemic Update: Special Report on HIV/AIDS. December 2006. [Full Text].

57. UNAIDS. Report on the Global AIDS Epidemic 2006. May, 2006.

58. United Nations Office on Drugs and Crime. 2007 World Drug Report. [Full Text].

59. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998 Jun. 113 Suppl 1:75-80. [Medline].

60. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999 Jul. 94(7):961-72. [Medline].

61. Whynot EM. Women who use injection drugs: the social context of risk. CMAJ. 1998 Aug 25. 159(4):355-8. [Medline].

Gloria J Baciewicz, MD Director of Addiction Psychiatry Program, Clinical Associate Professor, Department of Psychiatry, Strong Memorial Hospital, University of Rochester

Gloria J Baciewicz, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Psychiatric Association, American Society of Addiction Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Eduardo Dunayevich, MD Executive Director, Clinical Development, Amgen

Eduardo Dunayevich, MD is a member of the following medical societies: Schizophrenia International Research Society

Disclosure: Received salary from Amgen for employment; Received stock from Amgen for employment.

Barry I Liskow, MD Professor of Psychiatry, Vice Chairman, Psychiatry Department, Director, Psychiatric Outpatient Clinic, The University of Kansas Medical Center

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article